Added to YB: 2025-02-18
Pitch date: 2025-01-01
CATX [bullish]
Perspective Therapeutics, Inc.
+19.44%
current return
Author Info
No bio for this author
Company Info
Perspective Therapeutics, Inc., a radiopharmaceutical development company, develops and commercializes precision targeted alpha therapies (TAT) to treat cancer in the United States.
Market Cap
N/A
Pitch Price
$3.24
Price Target
21.00 (+443%)
Dividend
N/A
EV/EBITDA
N/A
P/E
-2.65
EV/Sales
238.33
Sector
Biotechnology
Category
special_situation
Perspective Therapeutics, Inc. - $CATX
CATX: Negative EV radiopharma biotech with 4-5x+ upside. Promising drugs/platform in hot M&A space. Recent trial disappointing due to underdosing, but fixable. Lead isotope PB-212 easier to manufacture/administer. $267M cash runway to mid-2026. Takeout potential at $1bn+ like peers. Catalysts: M&A, trial progress, FDA updates.
Read full article (11 min)